Osaka, Japan-based Takeda – which bought Swiss drugmaker Nycomed in September last year – said the cuts will be across its R&D and commercial operations with 2,100 jobs being lost in Europe and the remainder being in the US.
Takeda also said that as part of the integration plan it will consolidate its R&D (research and development) sites in Europe but did not go into specifics.
“The necessary cost for this plan is estimated approximately Yen 70bn ($911m) in total during fiscal 2011 – 2015. During this period, Takeda will achieve cost synergies of approximately Yen 200bn.
The firm also forecast that the financial impact of the cuts in the financial year ending in March will be around Yen 35bn and said that it will revise its forecasts accordingly.